NEURO-VISION, INC. – Trademark Portfolio
Entity Type: 03
NEURO-VISION, INC. holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 9 (Computers & Electronics) — 2 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 3 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include NEURO-VISION. The owner is based in FORT MYERS, FL.
APPETITE & SMOKING CONTROL CENTERS
1951 COLONIAL BOULEVARD
FORT MYERS, FL 33907
Showing of trademarks Trademarks
Trademark Classifications
NEURO-VISION, INC.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Scientific and technological services; industrial analysis and research services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does NEURO-VISION, INC. have?
NEURO-VISION, INC. has 2 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 cancelled.
What trademark classes does NEURO-VISION, INC. file in?
NEURO-VISION, INC. files trademarks across 3 Nice Classification classes. The most active classes are Class 9 (Computers & Electronics), Class 42 (Computer & Scientific), Class 44 (Medical Services). Class 9 covers scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments.
What are NEURO-VISION, INC.'s most well-known trademarks?
NEURO-VISION, INC.'s registered trademark portfolio includes well-known marks such as NEURO-VISION. These are among 1 currently registered trademark in the portfolio.
What is NEURO-VISION, INC.'s trademark registration success rate?
NEURO-VISION, INC. has a 50% trademark registration rate, with 1 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.